<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257269</url>
  </required_header>
  <id_info>
    <org_study_id>031/06</org_study_id>
    <nct_id>NCT01257269</nct_id>
  </id_info>
  <brief_title>Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)</brief_title>
  <acronym>TTP registry</acronym>
  <official_title>Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mach-Gaensslen Foundation Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxalta Innovations GmbH, Wien, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder
      characterized by thrombocytopenia as a result of platelet consumption, microangiopathic
      hemolytic anemia, occlusion of the microvasculature with von Willebrand
      factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a
      severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1
      motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13
      gene mutations.

      Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman
      syndrome patients varies considerably without an apparent genotype-phenotype correlation. In
      2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family
      members to identify possible triggers of acute bouts of TTP, to document individual clinical
      courses and treatment requirements as well as possible side effects of long standing plasma
      substitution, e.g. alloantibody formation or viral infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Thrombocytopenia and microangiopathic hemolytic anemia together with a severely deficient
      ADAMTS13 activity confirm the diagnosis of acute thrombotic thrombocytopenic purpura (TTP).
      Today two forms of classical TTP are distinguished. The acquired form is caused by
      circulating auto-antibodies, mainly Immunoglobulin G (IgG), inhibiting ADAMTS13 (a
      disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) activity. In
      contrast, hereditary TTP, also known as Upshaw-Schulman syndrome (USS); #274150 Online
      Mendelian Inheritance in Man (OMIM), is the result of severe constitutional deficiency of
      ADAMTS13 due to compound heterozygous or homozygous mutations in the ADAMTS13 gene.

      The clinical course of USS is variable with rather mild courses in some of the patients
      requiring plasma infusions only in special situations (i.e. pregnancy), while in others
      severe courses with important sequelae and even death in early childhood occur. The reasons
      for the variable clinical presentation and treatment requirements have not been elucidated.
      It seems likely, that additional, hitherto unidentified factors besides severe ADAMTS13
      deficiency modify the clinical course.

      At present, the clinical symptoms and laboratory values on which to base treatment regimens
      for hereditary TTP are poorly understood. Furthermore, increasing awareness of hereditary TTP
      results in rising numbers of patients in need of treatment and/or prophylaxis. However,
      currently very little is known on side effects of long standing plasma substitution.
      Alloimmunization with the formation of antibodies acting as inhibitors of treatment are well
      known in other congenital coagulation factor deficiencies (e.g. hemophilia A), but so far no
      case of treated hereditary TTP with subsequent antibody formation has been reported. It is
      the aim of the hereditary TTP Registry to provide information on the clinical course of the
      disease in as many patients as possible and therefore help to establish recommendations on
      the necessity, modalities, and risks of prophylactic plasma therapy in patients with
      hereditary TTP. Furthermore, it will help to gain detailed insight into triggers and risk
      factors of acute bouts of TTP.

      Moreover, the hereditary TTP Registry will provide information for family members on their
      risk to develop TTP-like or TTP-related disorders.

      Objective

      Primary objective: Collection of as much information as possible on the clinical
      presentation, disease course, disease-modifying factors, and treatment modalities of patients
      suffering from hereditary thrombotic thrombocytopenic purpura (TTP).

      Secondary objective: To document potential adversary effects of (long-term) plasma treatment
      in patients with hereditary thrombotic thrombocytopenic purpura (TTP).

      Methods

      The TTP Registry is designed to collect both retrospective and prospective clinical,
      molecular, and observational data on patients with confirmed or suspected hereditary TTP.
      Additionally, the Registry will collect data from family members of TTP patients enrolled in
      the Registry. The Registry will enroll as many confirmed or suspected hereditary TTP patients
      and their family members as possible; there is no cap on enrollment. The Registry enrollment
      and follow-up periods are open-ended. The endpoints for patients with confirmed or suspected
      hereditary TTP and family members are death or withdrawal of consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical presentation and disease course in hereditary TTP</measure>
    <time_frame>every year until death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of disease-modifying factors, including genotype-phenotype correlation</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment requirements in hereditary TTP patients</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of potential adversary effects of (long-term) plasma treatment</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of hereditary TTP</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical course in family members</measure>
    <time_frame>every year until death</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Congenital Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Familial Thrombotic Thrombocytopenic Purpura</condition>
  <condition>Thrombotic Thrombocytopenic Purpura, Congenital</condition>
  <condition>Upshaw-Schulman Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Family members of patients with confirmed hereditary TTP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>No interventions planned: treatment of patients at the discretion of the treating/responsible physician</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with either confirmed or with suspected hereditary TTP and their family members
        are eligible for enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe ADAMTS13 deficiency ( â‰¤ 10% activity) and no ADAMTS 13 inhibitor on two or more
             occasions at least one month apart

          -  Being a family member of a confirmed or suspected patient

          -  Molecular analysis of ADAMTS13 gene with one or more mutations and/or positive
             infusion trial (full recovered ADAMTS13 activity after infused fresh frozen plasma
             (FFP) with a plasma half-life of 2-4 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna A Kremer Hovinga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernhard LÃ¤mmle, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center, Center for Thrombosis and Hemostasis, Mainz, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshihiro Fujimura, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Hematology and Blood Transfusion, Coagulation Laboratory, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petter Quist-Paulsen, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, St Olavs Hospital, 7006 Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. George, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oklahoma Health Sciences Center, Department of Medicine, United States of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul N Knoebl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna, Div. Hematology and Hemostasis, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna A Kremer Hovinga, MD</last_name>
    <phone>+41 31 632 02 65</phone>
    <email>johanna.kremer@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anette van Dorland, Ph.D.</last_name>
    <phone>+41 31 632 56 90</phone>
    <email>anette.vandorland@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73126-0901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James N. George, M.D.</last_name>
      <phone>405-271-4222</phone>
      <email>james-george@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>James N. George, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Medicine 1, Div. Hematology and Hemostasis Waehringer Guertel 18-20</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul N. Knoebl, M.D.</last_name>
      <phone>+43 1 40400 4410</phone>
      <email>paul.knoebl@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Paul N. Knoebl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion, Coagulation Laboratory, U nemocnice 1</name>
      <address>
        <city>Prague 2</city>
        <zip>CZ-12820</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
      <phone>+420 2 2197 271</phone>
      <email>Ingrid.Hrachovinova@uhkt.cz</email>
    </contact>
    <investigator>
      <last_name>Ingrid Hrachovinova, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Martinistr 52</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
      <phone>+49 40 7410 54270</phone>
      <email>schneppenheim@uke.de</email>
    </contact>
    <investigator>
      <last_name>Reinhard Schneppenheim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nara Medical University, Department of Blood Transfusion Medicine, Shijyo-cho 840</name>
      <address>
        <city>Kashihara city</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihiro Fujimura, M.D.</last_name>
      <phone>+81 744 22 3051</phone>
      <phone_ext>3289</phone_ext>
      <email>yoshifuji325@naramed-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshihiro Fujimura, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trondheim University St Olavs Hospital, Department of Hematology, PO Box 3250 Sluppen</name>
      <address>
        <city>Trondheim</city>
        <zip>NO-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Quist-Paulsen, M.D., Ph.D.</last_name>
      <phone>+47 815 55 850</phone>
      <email>Petter.Quist-Paulsen@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Sophie von Krogh, M.D.</last_name>
      <phone>+47 815 55 850</phone>
      <email>Anne-Sophie.von.Krogh@stolav.no</email>
    </contact_backup>
    <investigator>
      <last_name>Petter Quist-Paulsen, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie von Krogh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna A Kremer Hovinga, MD</last_name>
      <phone>+41 31 632 02 65</phone>
      <email>johanna.kremer@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Isabella Aebi, BMA</last_name>
      <phone>+41 31 632 77 16</phone>
      <email>isabella.aebi-huber@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna A Kremer Hovinga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ttpregistry.net</url>
    <description>Additional information</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombotic thrombocytopenic purpura</keyword>
  <keyword>ADAMTS13</keyword>
  <keyword>Von Willebrand factor</keyword>
  <keyword>Von Willebrand factor cleaving protease</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Hemolytic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Fasciitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

